Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| V-Go is being managed for improved profitability as we continue to focus on improving our margins by producing COGS as well as improving gross to nets |
| As you can see, our insiders picked up some stock in the next few weeks and hosted our Board Meeting because we believe we're undervalued and we're very confident in our future |
| In Q4, we had record revenue for Tyvaso on both royalty and collaboration manufacturing, along with record production on Tyvaso cartridges |
| The fourth quarter was the second straight quarter with net income and positive earnings per share |
| We finished a year in the strongest position we have been in, in terms of financial ability, as well as by selling the Tyvaso -- 1% of our Tyvaso royalty for $150 million upfront and $50 million in revenue milestones |
| And people ask me, why am I excited about our program? And why am I confident? Well, the reason we are excited is, one, when we purchased the product, there was preclinical data showing an improvement in bacterial recovery in the lung model that they used |
| To summarize, a very successful 2023, we doubled our total revenues to almost $200 million versus the prior year |
| Fourth quarter was the second successive quarter of positive contribution from our endocrine business unit |
| So we feel very good about where we are in a one-two punch with INHALE-1 and INHALE-3 |
| We think that's good enough for PEDS approval |
| And we think MannKind indirectly benefits as more competition does come |
| 2024 should be another stellar year for MannKind, as we are financially prime to drive our commercial and clinical priorities and deliver increased shareholder value |
| And the good news is we have a great team, who's working extremely hard to make sure we get these INDs in to get the INHALE-1 and INHALE-3 study wrapped up |
| We're in a great position because of Steve's vision and leadership over the last seven years |
| As we look at our future, it's extremely exciting and I'm never more motivated to ensure we deliver on all key operational opportunities in front of us |
| We're super excited |
| We had record production in Q4 |
| V-Go net revenue improved versus the third quarter of 2023 by $0.2 million, mainly due to improved gross to nets |
| We think this is an important metric that is successful, and if we see a clinical advantage on highs or lows, that's upside to our expectation |
| But assuming that's on track, then we feel very good about wrapping up this trial to bring this to patients very quickly |
| The reason I'm excited about this program is our 28-day Tox data was very clean |
| As I presented at JPMorgan in January, our ability to grow double-digits for the foreseeable future looks bright when you see, in 2023, our total revenue approached $200 million, almost 100% growth year-over-year |
| We're very excited about Tyvaso DPI and what it's going to bring to patients and anticipate hopefully positive milestones for Tyvaso in the future and, therefore, want to preserve 90% of that value for our shareholders |
| We're super excited about the future |
| And we think there we have a significant clinical advantage, as well as a convenience advantage that, you know, we should be able to displace or grow that market opportunity very quickly as we enter it |
| A key component to DPI's advantage is the ease and convenience of the low-resistance device compared with other high-resistance devices |
| 2023 was a year of substantial revenue growth for the Company in terms of both percentage and dollar growth |
| Our total revenues grew a robust 62% versus fourth quarter 2022, and 99% for the 2023 full-year period, primarily due to the growth in our Tyvaso DPI-related revenues |
| I'll be doing non-deal road shows with Steve over the coming months to get the word out as we feel like MannKind is at the best inflection point with the best team in the industry, cash on the balance sheet and multiple shots on goal in terms of data read-outs to drive future growth |
| We purchased V-Go, which made our endocrine division more sustainable and brought us a couple thousand new prescribers, and Tyvaso DPI has been ahead of all the expectations since its approval |
| Statement |
|---|
| What we do also know is that there's severe GI toxicities, which limits patients acceptance and uptake and prescriber adoption |
| And it's why I think you're going to see continued lack of investment because you have to be -- either have enough capital to go through with it |
| So from my perspective Tyvaso DPI is delivered on all parameters above and beyond expectations, despite an under-forecast launch, which put a lot of pressure on MannKind |
| Revenues were 13% lower versus 2022, primarily due to lower patient demand and higher growth to nets as a percentage of gross revenues, partially offset by price |
| We knew roughly 20%, 30% of our Type 1s use Afrezza intermittently, which kind of hurts your refill rates, right? And then we know Type 2s are not as compliant as we want to be |
| Michael Castagna Oren, these are two great questions and I think it's the biggest challenge to developing products for NTM |
| And I think the reality is there are risks in this population |
| Innovation takes time and disruption is even harder |
| People also miss that |
| So that'll be an important aspect that we did struggle with the FDA saying, why are you the only country in the world that wants this sputum plus PRO, where we don't have the same demand yet in other countries around the world |
| I think the challenge with adding Afrezza on top of pumps besides the FDA, I'll just put that out there, is really the need that a patient sees |
| And we think that makes the PRO a difficult tool and therefore we tried to make it a secondary endpoint |
| And you can see at baseline, just unaided awareness of a present, what people's perceptions were in terms of unattracted, apathetic, attracted or passionate |
| We would not be going to the children if we were worried about the safety of our product |
| Nothing slowed down there |
| And two, we didn't want to disrupt the Afrezza field team |
| At the same time, we want to deep risk on the debt side of our Company |
| And I think that the pump data within INHALE-3 is going to have to hold up in every objective way in terms of reducing high or reducing lows or improving A1C or timing range |
| We know that's an FDA challenge |
| And we have a decreased risk relative to the landscape that has failed in IPS development because we already know this molecule works in IPS |
Please consider a small donation if you think this website provides you with relevant information